This creates theoretical concerns about cancer risk that require serious consideration
Common Protocol: BPC-157: 250500 mcg daily, subcutaneous near injury or systemic TB500: 25 mg per week, split into 23 injections Cycle: 46 weeks, followed by reassessment 2
Selective GH Release No ACTH or Cortisol Effect Unlike GHRP-6 and GHRP-2, which both resulted in elevated plasma ACTH and cortisol levels in swine models, Ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation alone even at doses more than 200-fold higher than the ED50 for GH release
Wilsons disease or copper overload
Once reconstituted, store at 28C and use within 2530 days
Water retention is a probable side effect of Ipamorelin, attributed to its influence on hormone levels and fluid balance